Work

P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.08.530

Authors: K. Nishino, J. Shih, C. Lovly, K. Nakagawa, M. Reck, E. Garon, M. Ceccarelli, S. Wijayawardana, C. Visseren-Grul, E. Nadal

Institutions: Osaka International Cancer Institute, National Taiwan University Hospital, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Kindai University, German Center for Lung Research, University of California, Los Angeles, Eli Lilly (United States), Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3206231694

Cites:

Cited by:

Related to: 10